What Will Happen to Biostage Incorporated (NASDAQ:BSTG) Next? The Stock Has Decline in Shorts

June 19, 2017 - By Dolores Ford

 What Will Happen to Biostage Incorporated (NASDAQ:BSTG) Next? The Stock Has Decline in Shorts

The stock of Biostage Incorporated (NASDAQ:BSTG) registered a decrease of 8.05% in short interest. BSTG’s total short interest was 2.66 million shares in June as published by FINRA. Its down 8.05% from 2.90M shares, reported previously. With 402,300 shares average volume, it will take short sellers 7 days to cover their BSTG’s short positions. The short interest to Biostage Incorporated’s float is 7.81%.

About 579,488 shares traded or 17.95% up from the average. Biostage Inc (NASDAQ:BSTG) has declined 78.72% since June 19, 2016 and is downtrending. It has underperformed by 95.42% the S&P500.

Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The company has market cap of $11.81 million. The Firm is engaged in developing bioengineered organ implants based on its Cellframe technology. It currently has negative earnings. The Company’s Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.

More notable recent Biostage Inc (NASDAQ:BSTG) news were published by: Prnewswire.com which released: “Biostage Announces Receipt of Nasdaq Listing Determination” on May 22, 2017, also Prnewswire.com with their article: “Biostage Reports 2017 First Quarter Financial Results and Provides Business Update” published on May 11, 2017, Prnewswire.com published: “Biostage Announces $8.0 Million Public Offering” on February 10, 2017. More interesting news about Biostage Inc (NASDAQ:BSTG) were released by: Prnewswire.com and their article: “Biostage to Present at Biotech Showcaseâ„¢ 2017” published on January 06, 2017 as well as Prnewswire.com‘s news article titled: “Biostage Successfully Regenerates Esophagus in Groundbreaking Pre-Clinical …” with publication date: May 12, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.